351 related articles for article (PubMed ID: 25036232)
1. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study.
Tanaka Y; Kubo S; Yamanaka H; Amano K; Hirata S; Tanaka E; Nagasawa H; Yasuoka H; Takeuchi T
Mod Rheumatol; 2014 Sep; 24(5):754-62. PubMed ID: 25036232
[TBL] [Abstract][Full Text] [Related]
2. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.
Kubo S; Saito K; Hirata S; Fukuyo S; Yamaoka K; Sawamukai N; Nawata M; Iwata S; Mizuno Y; Tanaka Y
Mod Rheumatol; 2014 Jan; 24(1):42-51. PubMed ID: 24261758
[TBL] [Abstract][Full Text] [Related]
3. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y
Clin Exp Rheumatol; 2016; 34(5):834-841. PubMed ID: 27607196
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
[TBL] [Abstract][Full Text] [Related]
5. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
6. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R
Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865
[TBL] [Abstract][Full Text] [Related]
7. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial.
Kremer JM; Peterfy C; Russell AS; Emery P; Abud-Mendoza C; Sibilia J; Becker JC; Westhovens R; Genant HK
J Rheumatol; 2014 Jun; 41(6):1077-87. PubMed ID: 24786925
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
9. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
[TBL] [Abstract][Full Text] [Related]
10. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.
Westhovens R; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Helfrick R; Bathon J
Ann Rheum Dis; 2009 Dec; 68(12):1870-7. PubMed ID: 19124524
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
[TBL] [Abstract][Full Text] [Related]
13. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
14. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
[TBL] [Abstract][Full Text] [Related]
15. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).
Takeuchi T; Yamanaka H; Inoue E; Nagasawa H; Nawata M; Ikari K; Saito K; Sekiguchi N; Sato E; Kameda H; Iwata S; Mochizuki T; Amano K; Tanaka Y
Mod Rheumatol; 2008; 18(5):447-54. PubMed ID: 18493716
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
[TBL] [Abstract][Full Text] [Related]
17. Use of abatacept in rheumatoid arthritis.
von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
[TBL] [Abstract][Full Text] [Related]
18. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B.
Kim PS; Ho GY; Prete PE; Furst DE
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1265-8. PubMed ID: 22392695
[TBL] [Abstract][Full Text] [Related]
20. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
